356 related articles for article (PubMed ID: 16204057)
1. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.
Wong CM; Yam JW; Ching YP; Yau TO; Leung TH; Jin DY; Ng IO
Cancer Res; 2005 Oct; 65(19):8861-8. PubMed ID: 16204057
[TBL] [Abstract][Full Text] [Related]
2. The intracellular stability of DLC1 is regulated by the 26S proteasome in human hepatocellular carcinoma cell line Hep3B.
Luo HW; Luo QP; Yuan Y; Zhu XY; Huang SF; Peng Z; Li CL; Huang ZG; Feng WL
Biochem Biophys Res Commun; 2011 Jan; 404(1):279-83. PubMed ID: 21130076
[TBL] [Abstract][Full Text] [Related]
3. Akt phosphorylation of deleted in liver cancer 1 abrogates its suppression of liver cancer tumorigenesis and metastasis.
Ko FC; Chan LK; Tung EK; Lowe SW; Ng IO; Yam JW
Gastroenterology; 2010 Oct; 139(4):1397-407. PubMed ID: 20600027
[TBL] [Abstract][Full Text] [Related]
4. Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma.
Ko FC; Yeung YS; Wong CM; Chan LK; Poon RT; Ng IO; Yam JW
Liver Int; 2010 Jan; 30(1):139-48. PubMed ID: 19874489
[TBL] [Abstract][Full Text] [Related]
5. Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma.
Wong CC; Wong CM; Ko FC; Chan LK; Ching YP; Yam JW; Ng IO
PLoS One; 2008 Jul; 3(7):e2779. PubMed ID: 18648664
[TBL] [Abstract][Full Text] [Related]
6. DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma.
Kim TY; Lee JW; Kim HP; Jong HS; Kim TY; Jung M; Bang YJ
Biochem Biophys Res Commun; 2007 Mar; 355(1):72-7. PubMed ID: 17292327
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth.
Chung GE; Yoon JH; Lee JH; Kim HY; Myung SJ; Yu SJ; Lee SH; Lee SM; Kim YJ; Lee HS
Oncol Rep; 2011 Jun; 25(6):1739-46. PubMed ID: 21455586
[TBL] [Abstract][Full Text] [Related]
8. The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration.
Zhong D; Zhang J; Yang S; Soh UJ; Buschdorf JP; Zhou YT; Yang D; Low BC
J Cell Sci; 2009 Feb; 122(Pt 3):414-24. PubMed ID: 19158340
[TBL] [Abstract][Full Text] [Related]
9. The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation.
Scholz RP; Gustafsson JO; Hoffmann P; Jaiswal M; Ahmadian MR; Eisler SA; Erlmann P; Schmid S; Hausser A; Olayioye MA
Exp Cell Res; 2011 Feb; 317(4):496-503. PubMed ID: 21087603
[TBL] [Abstract][Full Text] [Related]
10. Morphological changes and nuclear translocation of DLC1 tumor suppressor protein precede apoptosis in human non-small cell lung carcinoma cells.
Yuan BZ; Jefferson AM; Millecchia L; Popescu NC; Reynolds SH
Exp Cell Res; 2007 Nov; 313(18):3868-80. PubMed ID: 17888903
[TBL] [Abstract][Full Text] [Related]
11. Deleted in liver cancer 2 suppresses cell growth via the regulation of the Raf-1-ERK1/2-p70S6K signalling pathway.
Leung TH; Yam JW; Chan LK; Ching YP; Ng IO
Liver Int; 2010 Oct; 30(9):1315-23. PubMed ID: 20629949
[TBL] [Abstract][Full Text] [Related]
12. Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells.
Zhou X; Thorgeirsson SS; Popescu NC
Oncogene; 2004 Feb; 23(6):1308-13. PubMed ID: 14647417
[TBL] [Abstract][Full Text] [Related]
13. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression.
Yam JW; Ko FC; Chan CY; Jin DY; Ng IO
Cancer Res; 2006 Sep; 66(17):8367-72. PubMed ID: 16951145
[TBL] [Abstract][Full Text] [Related]
14. DLC1 interacts with 14-3-3 proteins to inhibit RhoGAP activity and block nucleocytoplasmic shuttling.
Scholz RP; Regner J; Theil A; Erlmann P; Holeiter G; Jähne R; Schmid S; Hausser A; Olayioye MA
J Cell Sci; 2009 Jan; 122(Pt 1):92-102. PubMed ID: 19066281
[TBL] [Abstract][Full Text] [Related]
15. RhoE is frequently down-regulated in hepatocellular carcinoma (HCC) and suppresses HCC invasion through antagonizing the Rho/Rho-kinase/myosin phosphatase target pathway.
Ma W; Wong CC; Tung EK; Wong CM; Ng IO
Hepatology; 2013 Jan; 57(1):152-61. PubMed ID: 22829315
[TBL] [Abstract][Full Text] [Related]
16. Restoration of DLC1 gene inhibits proliferation and migration of human colon cancer HT29 cells.
Wu PP; Jin YL; Shang YF; Jin Z; Wu P; Huang PL
Ann Clin Lab Sci; 2009; 39(3):263-9. PubMed ID: 19667410
[TBL] [Abstract][Full Text] [Related]
17. DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion.
Tripathi V; Popescu NC; Zimonjic DB
Oncogene; 2014 Feb; 33(6):724-33. PubMed ID: 23376848
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of invasion and metastasis of hepatocellular carcinoma cells via targeting RhoC in vitro and in vivo.
Wang W; Wu F; Fang F; Tao Y; Yang L
Clin Cancer Res; 2008 Nov; 14(21):6804-12. PubMed ID: 18980974
[TBL] [Abstract][Full Text] [Related]
19. Focal adhesion-localization of START-GAP1/DLC1 is essential for cell motility and morphology.
Kawai K; Iwamae Y; Yamaga M; Kiyota M; Ishii H; Hirata H; Homma Y; Yagisawa H
Genes Cells; 2009 Feb; 14(2):227-41. PubMed ID: 19170769
[TBL] [Abstract][Full Text] [Related]
20. The human LIS1 is downregulated in hepatocellular carcinoma and plays a tumor suppressor function.
Xing Z; Tang X; Gao Y; Da L; Song H; Wang S; Tiollais P; Li T; Zhao M
Biochem Biophys Res Commun; 2011 Jun; 409(2):193-9. PubMed ID: 21569763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
